Grand Rounds
  Most Recent Cases
  Dates of Case
  Type of Case
  Submit a Grand Round.
  Register with DJO to receive personalized updates.

If you're already a
member, please sign in.
A 39-year-old woman with unilateral metamorphosias
Digital Journal of Ophthalmology 2011
Volume 17, Number 4
November 20, 2011
DOI: 10.5693/djo.03.2011.11.001
Printer Friendly

Download PDF



Lígia Ribeiro | Department of Ophthalmology, Centro Hospitalar Vila Nova de Gaia, Portugal
Sidnei Barge | Department of Ophthalmology, Centro Hospitalar Vila Nova de Gaia, Portugal
Luís Silva | Department of Ophthalmology, Centro Hospitalar Vila Nova de Gaia, Portugal
Arnaldo Brandão | Department of Ophthalmology, Centro Hospitalar Vila Nova de Gaia, Portugal
Dália Meira | Department of Ophthalmology, Centro Hospitalar Vila Nova de Gaia, Portugal
Treatment
The patient was treated with two monthly intravitreal injections of 0.05 mL/0.5 mg ranibizumab, without ocular or systemic complications.

Four months after presentation, her visual acuity had improved to 1.0 and the metamorphopsias had resolved. Fluorescein angiography showed resolution of the choroidal neovascular lesion and complete resolution of the hemorrhage (Figure 2). Fluorescein angiography at 18 months' follow-up showed no recurrence of the choroidal neovascular membrane and her vision remained stable. No systemic or ocular adverse events were noted.
top
Figure 2
Fundus photographs and fluorescein angiograms of left eye before and 1, 4, and 18 months after intravitreal ranibizumab injections showing resolution of the hemorrhage and the choroidal neovascular membrane. The pretreatment fundus photograph shows a juxtafoveal choroidal neovascular membrane with multiple small chorioretinal lesions. Early and late phases of fluorescein angiogram showed window defects with no evidence of leakage.